Which sequence correctly describes digoxin's mechanism leading to positive inotropy?
Choose an answer, then check it.
Clinical Pharmacology · Heart Failure and Angina Medications
Cardiac Glycosides
On this page 6 sections
In 30 seconds
Digoxin is the classic cardiac glycoside: it makes the heart squeeze harder while slowing it down. It boosts contractility by altering calcium handling inside heart muscle cells and slows heart rate by increasing vagal tone. Modern practice reserves it for symptom relief and hospitalization reduction in heart failure with reduced ejection fraction, and for rate control in atrial fibrillation when other options fall short. It is respected, and feared, for a narrow therapeutic index, meaning the gap between a helpful dose and a toxic one is small.
The college version
Mechanism of Action
Digoxin binds to and inhibits the sodium-potassium ATPase pump on the cardiac myocyte membrane. This pump normally pushes sodium out of the cell and potassium in, using energy from ATP. When digoxin blocks it, sodium accumulates inside the cell. That rising intracellular sodium changes the gradient the sodium-calcium exchanger relies on. This exchanger normally uses the inward sodium gradient to pump calcium out of the cell; with a weaker gradient, it extrudes less calcium, so calcium builds up inside the cell too. More intracellular calcium means more calcium available to the contractile proteins, actin and myosin, producing a stronger contraction. This is positive inotropy, an increase in the force of contraction without necessarily increasing heart rate.
Separately, digoxin increases vagal (parasympathetic) tone at the sinoatrial and atrioventricular nodes, producing a negative chronotropic effect (slower heart rate) and a negative dromotropic effect (slower AV conduction). This combination — a stronger contraction plus a slower, more organized rhythm — is what makes digoxin useful in two very different clinical situations.
Clinical Roles: HFrEF and Atrial Fibrillation
In heart failure with reduced ejection fraction, digoxin improves symptoms and reduces hospitalizations, but it does not extend survival. It is added on top of, not instead of, therapies proven to reduce mortality, such as guideline-directed neurohormonal blockers. It is best thought of as a symptom-and-hospitalization drug, not a life-prolonging one.
In atrial fibrillation, digoxin slows ventricular response through its effect on AV nodal conduction. Because its rate-controlling effect depends heavily on vagal tone, it works best at rest and is comparatively weak during exertion or high sympathetic states. This makes it a good fit for sedentary or relatively inactive patients, or as an option when beta-blockers or calcium channel blockers cannot be tolerated because of hypotension, bronchospasm, or advanced heart failure.
Narrow Therapeutic Index and Level Monitoring
Digoxin has a narrow therapeutic index: the dose that helps and the dose that harms sit close together, and individual variation in absorption, distribution, and elimination narrows this gap further. Serum digoxin concentration is therefore monitored periodically, and the blood draw must be timed correctly relative to the last dose, drawn as a trough well after the distribution phase has finished, rather than shortly after dosing when levels are transiently and misleadingly high. A level drawn too early can suggest toxicity that is not really present, or mask a level that will still climb further.
Potassium and Other Precipitants of Toxicity
Potassium is central to digoxin safety because digoxin and potassium compete for the same binding site on the sodium-potassium ATPase pump. When serum potassium is low, digoxin binds more readily and its effect is potentiated, so toxicity can occur even at a dose or level that would otherwise be considered acceptable. This is why loop and thiazide diuretics, which promote potassium loss, are a classic and common precipitant of digoxin toxicity in practice: a patient stable on digoxin can tip into toxicity simply because a diuretic dose lowered their potassium.
Other factors sensitize the heart to digoxin's effects as well. Hypomagnesemia potentiates toxicity much like hypokalemia does, and hypercalcemia adds to digoxin's calcium-driven effects on the myocardium, raising arrhythmia risk. Because digoxin is cleared largely by the kidneys, renal impairment lets the drug accumulate; advancing age often brings reduced renal function and lower lean body mass, both raising exposure for a given dose. Certain drugs raise digoxin levels by reducing its clearance or displacing it from tissue binding, including amiodarone, verapamil, and clarithromycin — adding any of these to a stable digoxin regimen warrants closer monitoring.
Recognizing and Managing Toxicity
Toxicity often announces itself with nonspecific gastrointestinal and neurologic symptoms before dangerous rhythm changes appear: anorexia, nausea and vomiting, fatigue, and confusion are common early clues, especially in older adults, where they may be mistaken for other illness. A more specific finding is visual disturbance, blurred or altered vision, a yellow-green tinge to vision, or halos around lights (chromatopsia), reflecting digoxin's effect on retinal cells. Cardiac signs range from bradycardia to a wide range of arrhythmias, since digoxin can produce almost any rhythm disturbance, sometimes combining unusually slow and unusually fast elements in the same patient.
Management starts with stopping the drug and correcting contributing factors, particularly low potassium and low magnesium, along with continuous cardiac monitoring. For severe or life-threatening toxicity, digoxin immune Fab is the specific antidote: antibody fragments that bind digoxin molecules directly, pulling the drug out of circulation and away from its site of action so it can be cleared.
Nursing Considerations
Before administering digoxin, the apical pulse is assessed for a full minute, since irregular and slow rhythms can be missed with a brief count or a radial pulse alone. A pulse that is unusually slow prompts holding the dose and notifying the prescriber rather than giving it as scheduled. Ongoing care includes watching for early toxicity signs, monitoring potassium and renal function, reviewing new medications for interactions, and teaching patients to report gastrointestinal symptoms, visual changes, or a sense that their heart is beating differently.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Imagine your heart muscle cells are like tiny hands gripping and releasing to make each heartbeat. Digoxin gums up a pump on the outside of those cells that normally trades sodium for potassium. When that pump slows down, sodium piles up inside the cell, and that extra sodium changes another swap going on: the cell can no longer push calcium back out as easily. So calcium builds up too, and calcium is what makes the gripping hands squeeze. More calcium, stronger squeeze. At the same time, digoxin turns up a "calm down" signal to the heart's natural pacemaker, so it beats a little slower and steadier.
Think of it like adding weights to your hands so each punch lands harder, while someone whispers "slow down" in your ear. That is great for a heart that is weak and beating too fast, but too much of it is like adding too many weights and whispering too loudly: the punches get sloppy and the rhythm falls apart. That is why doctors check blood levels carefully and watch potassium closely, since it sits right next to digoxin on that same pump and can tip things toward trouble if it runs low.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient on stable long-term digoxin therapy is newly started on amiodarone for rhythm control. Explain why this change warrants closer monitoring of the patient's digoxin therapy.
Show answer
Amiodarone can raise digoxin levels through reduced clearance and displacement, so adding it to a stable regimen increases toxicity risk even without a digoxin dose change, warranting reassessment of levels and clinical status.
Think of amiodarone as crowding the exit doors digoxin normally uses to leave the body, so digoxin lingers longer and builds up higher than before, even though nothing about the digoxin dose changed.
An older adult on digoxin reports new fatigue, poor appetite, and seeing yellow-tinged halos around lights. What should this prompt the nurse to consider, and what is one immediate nursing action?
Show answer
These symptoms (anorexia, fatigue, yellow-tinged visual halos) are classic signs of digoxin toxicity, so the nurse should suspect toxicity, hold the next dose, and notify the prescriber while arranging further evaluation such as a digoxin level and electrolyte check.
The body is sending warning signals, an upset stomach, no appetite, weird yellow-green vision, that say "too much digoxin on board," so the right move is to pause the medicine and get the patient checked rather than giving the next dose as usual.
Quick check
3 questions here. Answers stay hidden until you check.
A patient with atrial fibrillation who is largely sedentary and cannot tolerate beta-blockers is being considered for digoxin. Which statement best reflects an appropriate rationale?
Choose an answer, then check it.
A patient on digoxin is started on a loop diuretic for volume overload. Why does this combination raise concern for digoxin toxicity?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.